Cerenome, Inc. CNSY

Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today provided a third quarter 2026 business update for its wholly owned subsidiary, CNSide Diagnostics, LLC, highlighting gross payer billings, progress on Medicare coverage of its Tumor Cell Enumeration Test (TCE Tes

Management to provide updates on recent developments including diagnostic billing, market access & growth plansHOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced that management will host a conference call and webcast on Wednesday, September 30, 2026, at 8:30 a.m. Eastern Time to provide a business update on CNSide®, the Company's cerebrospinal fluid (CSF) diagnostic platfo

HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an in-network provider agreement with Blue Cross Blue Shield of Michigan (“BCBSM”), effective September 1, 2026, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. BCBSM serves approximately 5 million commercial and Medicare Advantage members through Blue Cross Blue Shiel

HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of Samantha Fowlkes as Vice President Head of Commercial Sales. Samantha will lead the commercial expansion of CNSide®, strengthening relationships across the oncology and pathology communities, and accelerate adoption of the CNSide platform by physicians and health systems. “Samantha brings more than two de

Capital will support continued CNSide® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028 HOUSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform of precision diagnostics, targeted therapeutics, and artificial intelligence, today announced that it has entered into a financing agreeme

Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial shows strong safety signal CNSide® cost-of-care analysis shows up to 47% reduction in monthly LM-related treatment costs HOUSTON, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”) today highlights data from two scientific posters presented

HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights. "Our team made substantial progress this quarter in advancing our integrated CNS oncology platform inclu

Agreement marks achievement of Cerenome’s full-year 2026 commercial payer coverage objective for CNSideHOUSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an in-network provider agreement with Health Care Service Corporation (“HCSC”), effective August 1, 2026, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. HCSC represen

Scalable revenue cycle ecosystem designed to support anticipated billing volumes; CNSide assay billing to begin in Q3 2026 with accumulated 2026 backlog of tests and concurrent case billingHOUSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has selected XiFin, Inc. (“XiFin”), a market leader in artificial intelligence (AI)-driven revenue cycle management (RCM) for dia

Formerly known as Plus Therapeutics, Cerenome integrates precision diagnostics, targeted therapeutics, and artificial intelligence to improve how CNS cancers are detected, treated, and understoodHOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective August 3, 2026, the Company’s name will become Cerenome, Inc. The Company's common stock will begin trading o